Skip to content

Released May 9, 2016, after the close

10-Q filed May 9, 2016, 39 days after period end · 0001144204-16-099933

Q1 2016 · 10-Q
Revenue$679.00K−59.9% vs Q1 2015no prior Q4 2015 on file
Net Income-$8.60MN/M vs Q1 2015N/M vs Q4 2015
EPS Diluted-$0.09N/M vs Q1 2015no prior Q4 2015 on file
Gross Profit$156,000−88.9%
Operating Income-$7,864,000N/M
Operating Cash Flow-$9,625,000N/M
Free Cash Flowderived-$9,876,000N/M
Margins · derived
Gross margin23.0%−60.4 pt vs Q1 2015
Operating margin-1158.2%−840.0 pt vs Q1 2015
Net margin-1266.3%−913.3 pt vs Q1 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2016Q1 2015Q1 2014Q1 2013
Revenue$679.00K$1.69M$6.70M$3.57M
Net Income-$8.60M-$5.97M-$7.35M-$4.32M
EPS Diluted-$0.09-$0.06$0.08$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR